Deniz Koçak Göl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Deniz Koçak Göl has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Ekrem Unal
Pediatric BMT Unit, Erciyes University Faculty of Medicine, Kayseri, Turkey
11 shared publications - Alper Ozcan
Erciyes University Faculty of Medicine, Department of Pediatrics Hematology and Oncology, Kayseri, Türkiye
8 shared publications - Ebru Yilmaz
Erciyes University Faculty of Medicine, Department of Pediatrics Hematology and Oncology, Kayseri, Türkiye
6 shared publications - Musa Karakukcu
Erciyes University Faculty of Medicine, Department of Pediatrics Hematology and Oncology, Kayseri, Türkiye
6 shared publications - Veysel Gök
Erciyes University Faculty of Medicine, Department of Pediatrics Hematology and Oncology, Kayseri, Türkiye
6 shared publications - Şefika Akyol
Department of Pediatric Hematology, School of Medicine, Dokuz Eylül University, İzmir, Türkiye
5 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 43 (2) , 194-197
Curing the “Incurable”: First Successful Hematopoietic Stem Cell Transplantation in Severe Hereditary Spherocytosis with Homozygous SPTA1 Variant and Hepatic Fibrosis
- 2 June 2026
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 43 (2) , 194-197
Open AccessCuring the “Incurable”: First Successful Hematopoietic Stem Cell Transplantation in Severe Hereditary Spherocytosis with Homozygous SPTA1 Variant and Hepatic Fibrosis
- 27 May 2025
- Published by Academician Publishing
- p. 899-904
Demir Metabolizması
- 27 May 2025
- Published by Academician Publishing
- p. 981-988
Kan Bileşenlerinin Özellikleri ve Transfüzyon Pratiği
- 27 May 2025
- Published by Academician Publishing
- p. 981-988
Kan Bileşenlerinin Özellikleri ve Transfüzyon Pratiği
- 27 May 2025
- Published by Academician Publishing
- p. 997-1002
Çocukluk Çağı Lösemileri
- Open Access
- 27 May 2025
- Published by Academician Publishing
Canpolat-Karakükcü-Dursun-Poyrazoğlu Pediatride Temel Bilgiler
- 27 May 2025
- Published by Academician Publishing
Open AccessCanpolat-Karakükcü-Dursun-Poyrazoğlu Pediatride Temel Bilgiler
- 4 May 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (7) , e31762
A Rare Intersection: Wilms Tumor in a Patient with PIGO Syndrome
- 4 May 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (7) , e31762
A Rare Intersection: Wilms Tumor in a Patient with PIGO Syndrome
- Open Access
- 24 April 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (4)
Clinical and laboratory aspects of patients diagnosed with various inherited platelet disorders
- 24 April 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (4)
Open AccessClinical and laboratory aspects of patients diagnosed with various inherited platelet disorders
- Open Access
- 7 April 2025
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 42 (2) , 158-160
Successful Treatment of Childhood Hodgkin’s Lymphoma and Secondary Myelofibrosis Resistant to Intensive Therapy, Including Allogeneic Transplantation
- 7 April 2025
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 42 (2) , 158-160
Open AccessSuccessful Treatment of Childhood Hodgkin’s Lymphoma and Secondary Myelofibrosis Resistant to Intensive Therapy, Including Allogeneic Transplantation
- Open Access
- 23 March 2025
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 6 (2) , 105-109
Platelet indices: a new tool for monitoring infantile hemangioma treatment
Aims: Infantile hemangioma (IH) is the most common benign vascular tumor in childhood. Diagnosis, treatment decisionmaking, and monitoring of the treatment are challenging. This study aims to investigate the utilization of platelet (PLT) indices as a marker in the follow-up of IH treatment. Methods: The patients who were admitted and followed up in the outpatient clinic of Erciyes University Department of Pediatric Hematology and Oncology were enrolled in the study. The demographical data, treatment results, and PLT indices of the patients at certain time points were analyzed retrospectively. PLT, mean platelet volume (MPV), and platelet distribution width (PDW) were measured at various time points: upon admission, after the first and second months of treatment, at treatment completion, and during rebound episodes in affected patients. Results: A general decrease in PLT, PDW, and MPV values was noted when comparing admission levels to the first month of treatment. The mean PLT count was 452.680/mm3 at admission, it decreased to 405.900/mm3 at the 1st month, 376.600/mm3 at the 2nd month and 359.900/mm3 at the end of treatment (p: 0,002). Besides MPV was evaluated, it was observed that while the mean was 10.43 fl at the time of admission, it decreased to 9.51 fl in the following months and the decline was statistically significant with a p value of 0,031. Lastly, regarding the mean PDW values, a decline was detected once again from 11.34 % to 10.2 % between the admission time and termination of the treatment with a statistically significant p value of
- 23 March 2025
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 6 (2) , 105-109
Open AccessPlatelet indices: a new tool for monitoring infantile hemangioma treatment
Aims: Infantile hemangioma (IH) is the most common benign vascular tumor in childhood. Diagnosis, treatment decisionmaking, and monitoring of the treatment are challenging. This study aims to investigate the utilization of platelet (PLT) indices as a marker in the follow-up of IH treatment. Methods: The patients who were admitted and followed up in the outpatient clinic of Erciyes University Department of Pediatric Hematology and Oncology were enrolled in the study. The demographical data, treatment results, and PLT indices of the patients at certain time points were analyzed retrospectively. PLT, mean platelet volume (MPV), and platelet distribution width (PDW) were measured at various time points: upon admission, after the first and second months of treatment, at treatment completion, and during rebound episodes in affected patients. Results: A general decrease in PLT, PDW, and MPV values was noted when comparing admission levels to the first month of treatment. The mean PLT count was 452.680/mm3 at admission, it decreased to 405.900/mm3 at the 1st month, 376.600/mm3 at the 2nd month and 359.900/mm3 at the end of treatment (p: 0,002). Besides MPV was evaluated, it was observed that while the mean was 10.43 fl at the time of admission, it decreased to 9.51 fl in the following months and the decline was statistically significant with a p value of 0,031. Lastly, regarding the mean PDW values, a decline was detected once again from 11.34 % to 10.2 % between the admission time and termination of the treatment with a statistically significant p value of
- Open Access
- 20 March 2025
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 6 (1) , 54-61
Rituximab in pediatric B-cell Non-Hodgkin Lymphoma: Clinical outcomes and prognostic implications
Objective: B-cell Non-Hodgkin Lymphoma (B-NHL) is an aggressive malignancy in children requiring prompt multidisciplinary management. This retrospective cohort study aims to evaluate the clinical characteristics, treatment outcomes, and impact of rituximab (RTX) in pediatric B-NHL patients. Methods: We retrospectively analyzed 62 pediatric B-NHL patients treated at tertiary centers. Patient demographics, clinical presentation, histopathological subtypes, disease stage, treatment regimens, and survival outcomes were assessed. Event-free survival (EFS) and overall survival (OS) rates were analyzed based on lactate dehydrogenase (LDH) levels and RTX administration. Results: The mean age at diagnosis was 8.73±4.3 years, with a male predominance (79%). The most common histological subtype was Burkitt lymphoma (BL) (53.2%), followed by diffuse large B-cell lymphoma (DLBCL) (33.8%). Advanced-stage disease (III-IV) was observed in 74.1% of cases. RTX was administered in 72.5% of patients, with a mean of 5.1±2.7 doses. Febrile neutropenia (FEN) was noted in 74.1%, with intensive care unit (ICU) admission required for seven patients. Mortality was observed in 12 (19.3%) patients, including all patients with primary immunodeficiency (PID). The 5-year EFS for the entire cohort was 67.2%, and OS was 81.3%. Patients with LDH 400 U/L (EFS: 49.6%, OS: 70.7%; p=0.004 and p=0.015, respectively). In RTX-treated patients without PID, EFS was 76.5% versus 73.2% in those without RTX, but the difference was not statistically significant (p=0.53). Conclusions: Although not statistically significant, EFS was found to be higher in the RTX-treated group, suggesting that adding RTX to standard chemotherapy regimens may improve survival, particularly for high-risk patients, though its benefit in low-risk cases remains uncertain. Despite improved survival, patients with PID had poor outcomes, likely due to increased infections and disseminated disease. Risk-adapted, targeted treatment strategies are essential for optimizing outcomes in pediatric B-NHL. Further large-scale, randomized controlled trials are needed to confirm the efficacy of RTX in different risk groups and to optimize treatment regimens for pediatric B-NHL.
- 20 March 2025
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 6 (1) , 54-61
Open AccessRituximab in pediatric B-cell Non-Hodgkin Lymphoma: Clinical outcomes and prognostic implications
Objective: B-cell Non-Hodgkin Lymphoma (B-NHL) is an aggressive malignancy in children requiring prompt multidisciplinary management. This retrospective cohort study aims to evaluate the clinical characteristics, treatment outcomes, and impact of rituximab (RTX) in pediatric B-NHL patients. Methods: We retrospectively analyzed 62 pediatric B-NHL patients treated at tertiary centers. Patient demographics, clinical presentation, histopathological subtypes, disease stage, treatment regimens, and survival outcomes were assessed. Event-free survival (EFS) and overall survival (OS) rates were analyzed based on lactate dehydrogenase (LDH) levels and RTX administration. Results: The mean age at diagnosis was 8.73±4.3 years, with a male predominance (79%). The most common histological subtype was Burkitt lymphoma (BL) (53.2%), followed by diffuse large B-cell lymphoma (DLBCL) (33.8%). Advanced-stage disease (III-IV) was observed in 74.1% of cases. RTX was administered in 72.5% of patients, with a mean of 5.1±2.7 doses. Febrile neutropenia (FEN) was noted in 74.1%, with intensive care unit (ICU) admission required for seven patients. Mortality was observed in 12 (19.3%) patients, including all patients with primary immunodeficiency (PID). The 5-year EFS for the entire cohort was 67.2%, and OS was 81.3%. Patients with LDH 400 U/L (EFS: 49.6%, OS: 70.7%; p=0.004 and p=0.015, respectively). In RTX-treated patients without PID, EFS was 76.5% versus 73.2% in those without RTX, but the difference was not statistically significant (p=0.53). Conclusions: Although not statistically significant, EFS was found to be higher in the RTX-treated group, suggesting that adding RTX to standard chemotherapy regimens may improve survival, particularly for high-risk patients, though its benefit in low-risk cases remains uncertain. Despite improved survival, patients with PID had poor outcomes, likely due to increased infections and disseminated disease. Risk-adapted, targeted treatment strategies are essential for optimizing outcomes in pediatric B-NHL. Further large-scale, randomized controlled trials are needed to confirm the efficacy of RTX in different risk groups and to optimize treatment regimens for pediatric B-NHL.